<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797380</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000703</org_study_id>
    <nct_id>NCT01797380</nct_id>
  </id_info>
  <brief_title>A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of escitalopram in treating depression in HIV seropositive women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the efficacy of escitalopram in treating depression in HIV seropositive women.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Depressive Symptoms</measure>
    <time_frame>9 weeks.</time_frame>
    <description>Depressive symptoms were assessed by questionaire at baseline and finally at the end of the study at 9 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Depression</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram tablet, 10mg, daily, 9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for duration of double-blind portion of trial</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10 mg po daily for duration of double-blind portion of trial</description>
    <arm_group_label>Active Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depression based on DSM-IV criteria;

          -  age 18-70 years;

          -  Greater than 15 on MADRS for severity of depression;

          -  HIV seropositive;

          -  no new antiviral medications over the past 2 months;

          -  involved in active treatment for HIV disease,

          -  negative serum pregnancy test

          -  Those subjects who are actively being treated for depression but show no improvement
             as defined by self-reported failure to improve with current treatment or residual
             depression as demonstrated by a MADRS of 15 or greater will be asked to participate in
             the study as well.

        Exclusion Criteria:

          -  The presence of an active and significant psychiatric disease other than Major
             Depressive Disorder as diagnosed on MINI in the last 3 months;

          -  meeting DSM-IV criteria for an Axis I disorder within the last three months, or
             meeting criteria for substance abuse within the last 12 months;

          -  current pregnancy or lactation if breast feeding;

          -  history of hypersensitivity, intolerance, or contraindication to LEX;

          -  baseline creatinine of 2.5 or greater;

          -  patients taking anticoagulants;

          -  history of diagnosed gastric or duodenal ulcer;

          -  history within past year of bleeding or clotting diathesis;

          -  lifetime history of myocardial infarction or cerebrovascular accident;

          -  history of surgery within the past 3 months;

          -  inability to follow study procedures or complete the study;

          -  the use of any antidepressant medications within 5 half-lives of randomization;

          -  women of child-bearing potential who will not agree to use approved means of birth
             control during the trial;

          -  other reason that the primary investigator believes that the subject will be unable to
             complete trial or has medical/psychiatric contraindications to the trial.

          -  Individuals who are currently being treated for depression and show significant
             improvements in their depression such that discontinuing their current antidepressant
             therapy would likely have negative clinical consequences will be excluded from
             participating in this study.

          -  Individuals who are or become suicidal will be excluded from this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barroso J. A review of fatigue in people with HIV infection. J Assoc Nurses AIDS Care. 1999 Sep-Oct;10(5):42-9. Review.</citation>
    <PMID>10491802</PMID>
  </reference>
  <reference>
    <citation>Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics. 2004 May-Jun;45(3):210-6.</citation>
    <PMID>15123845</PMID>
  </reference>
  <reference>
    <citation>Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003 Apr;25(4):1200-10.</citation>
    <PMID>12809966</PMID>
  </reference>
  <reference>
    <citation>Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS. 2005 Dec;19(12):813-22. Review.</citation>
    <PMID>16375613</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>February 25, 2013</results_first_submitted>
  <results_first_submitted_qc>April 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Active Drug</title>
          <description>Escitalopram tablet, 10mg, daily, 9 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">Terminated due to lack of enrollment</participants>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Terminated due to lack of enrollment</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Terminated study. Study terminated prior to interventions</population>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Active Drug</title>
          <description>Escitalopram tablet, 10mg, daily, 9 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Depressive Symptoms</title>
        <description>Depressive symptoms were assessed by questionaire at baseline and finally at the end of the study at 9 weeks.</description>
        <time_frame>9 weeks.</time_frame>
        <population>Terminated due to lack of recruitment. Five subjects were consented for the trial, but were not able to complete study or generate analyzable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>Escitalopram tablet, 10mg, daily, 9 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Depressive Symptoms</title>
          <description>Depressive symptoms were assessed by questionaire at baseline and finally at the end of the study at 9 weeks.</description>
          <population>Terminated due to lack of recruitment. Five subjects were consented for the trial, but were not able to complete study or generate analyzable data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study was terminated early due to failure to recruit.</time_frame>
      <desc>Study was terminated before adverse events were noted.No participants were treated therefore no participants were analyzed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Active Drug</title>
          <description>Escitalopram tablet, 10mg, daily, 9 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harold Goforth, M.D.</name_or_title>
      <organization>Duke University Health Systems</organization>
      <phone>216-636-3999</phone>
      <email>goforth@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

